[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osteopenia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osteopenia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,47,75,108,142,166,197,225,262,289,326,351,375,395,420,444,482],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644834","functional-muscle-bone-incongruity-index-fkui-a-prospective-observational-study-100644834",false,"NCT07677033","Functional Muscle-Bone Incongruity Index (FKUI): A Prospective Observational Study","Functional Muscle-Bone Incongruity Index (FKUI): Combined Evaluation of Handgrip Strength, Total Hip Bone Mineral Density, and Lumbar-Hip Bone Mineral Density Discordance in Adults Undergoing DXA","FKUI","Inclusion Criteria:\n\n* Age 18 years or older\n* Attendance at the Physical Medicine and Rehabilitation outpatient clinic\n* Scheduled to undergo routine bone mineral density assessment by DXA as part of clinical evaluation\n* Ability to perform handgrip strength testing\n* Availability of lumbar spine and total hip bone mineral density measurements suitable for analysis\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Secondary causes of osteoporosis (e.g., hyperparathyroidism, Cushing syndrome, malignancy, or other conditions affecting bone metabolism)\n* History of metabolic bone disease\n* Major trauma or fracture within the previous 6 months\n* Upper extremity disorders that may significantly affect handgrip strength measurement (e.g., severe osteoarthritis, neurological disorders, major deformities)\n* DXA measurements that are technically inadequate or unsuitable for analysis\n* Refusal or inability to provide written informed consent","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","The Functional Muscle-Bone Incongruity Index (FKUI) is a novel approach developed to evaluate the relationship between muscle function and bone health. This prospective observational study aims to investigate the clinical applicability of FKUI, which combines handgrip strength, total hip bone mineral density (BMD), and lumbar-hip BMD discordance. Approximately 200 adult participants undergoing routine DXA assessment will be enrolled. The study will examine whether the combined evaluation of muscle function and bone health parameters provides a more comprehensive assessment of musculoskeletal status than individual measures alone.",[25,26,27,28],"Osteoporosis","Musculoskeletal Health","Sarcopenia","Osteopenia",[30,15,31,32,33],"Functional Muscle-Bone Incongruity Index FKUI","Bone Mineral Density","Hip-Spine Discordance","Handgrip Strength","RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-30","ACTUAL",{"date":40,"type":38},"2026-05-01",{"date":42,"type":21},"2027-05-01",{"name":44,"class":45},"Kanuni Sultan Suleyman Training and Research Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100558441","peripheral-mononuclear-cells-to-screen-monitor-and-stratify-the-population-at-risk-of-osteoporosis-and-fractures-100558441","NCT06551155","Peripheral Mononuclear Cells to Screen, Monitor and Stratify the Population at Risk of Osteoporosis and Fractures","Identification, Monitoring, and Classification of Patients at Risk of Osteoporosis and Fractures Using a Method Based on the Use of Mononuclear Cells From Peripheral Blood","DISCERN","Inclusion Criteria:\n\n* Healthy patients (at risk and undergoing periodic follow-up and\u002For attending outpatient visits for preventive screening)\n* Osteopenic patients with an available DXA\n* Osteoporotic patients (fractured and non-fractured) with an available DXA or, for fractured patients, a DXA prescribed as part of clinical practice\n* Aged ≥ 40 years of both sexes\n* Body Mass Index (BMI) between 18.5 and 29.9\n\nExclusion Criteria:\n\n* Hematopoietic system disorders (hemolytic, aplastic, and neoplastic anemias)\n* Coagulation disorders (hereditary or secondary to other disorders)\n* Infections (including HIV-HBV-HCV positivity)\n* Neoplastic diseases (primary and\u002For secondary tumors)\n* Pregnancy or breastfeeding\n* Alcohol consumption (\\>20 g of alcohol per day currently or in the past)\n* Smoking (\\>10 cigarettes per day, currently or in the past)\n* Diabetes\n* Treatment with therapeutic agents that may interfere with hematopoiesis (corticosteroids, immunosuppressive agents, cytotoxic drugs)","40 Years",{"count":57,"type":21},120,"Osteoporosis (OP) is one of most common age-associated and chronic metabolic bone diseases, featured by a decrease of bone mineral density (BMD) that increases the risk of bone fractures.OP guidelines agree that Dual-X-ray Absorptiometry (DXA) is the gold standard for BMD assessment, but for the different OP stages screening and diagnosis, BMD by itself is not an accurate predictor. Thus, OP is often misdiagnosed. Aim of the this study is to improve a tool for OP diagnosis based on the ability of circulating peripheral blood mononuclear cells (PBMCs) to maintain or not their in vitro viability (IRCCS Istituto Ortopedico Rizzoli European patent n.3008470 March 21, 2018) for the measurement of the different OP severity levels, also considering specific gender related differences.",[25,28,60],"Osteoporosis Fracture",[62,63,64],"peripheral blood mononuclear cells","screening","diagnosis","2026-05-25",{"date":67,"type":38},"2026-05-28",{"date":69,"type":38},"2024-08-05",{"date":71,"type":21},"2027-02-20",{"name":73,"class":45},"Istituto Ortopedico Rizzoli",2,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":46},"100599366","routine-validation-and-reproducibility-testing-of-laboratory-assays-and-research-techniques-used-for-endocrine-cardiometabolic-and-musculoskeletal-disorder-research-vald-100599366","NCT07083557","Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)","VALD","Inclusion Criteria:\n\n* ≥18 and ≤100 years of age\n* body mass index ≥16.0 and ≤60 kg\u002Fm2\n\nExclusion Criteria:\n\n* \\\u003C18 and \\>100 years of age\n* body mass index \\\u003C16.0 or \\>60 kg\u002Fm2\n* allergies, intolerances, or dietary restrictions to meal ingredients, vegans or vegetarians\n* use of medications or dietary supplements (e.g., anti-inflammatories, immune modulators, etc) that could interfere with the particular assay\u002Ftechniques being evaluated\n* engaged in regular structured exercise \\>150 min per week unless needed for validation of the assay\u002Ftechnique being evaluated\n* significant organ system dysfunction or diseases, except those that are sought for validation of the assay\u002Ftechnique being evaluated\n* alcohol use disorder as defined by the National Institute of Alcohol Abuse and Alcoholism or use of controlled substances unless alcohol use disorder is required for validation of the assay\u002Ftechnique being evaluated\n* pregnant women, persons who smoke, prisoners, and inability to grant voluntary informed consent.",true,"100 Years",{"count":85,"type":21},100,"The purpose of this research study is to validate (check the accuracy of) laboratory assays, intravenous catheter insertion, and equipment or devices and their reproducibility, which is necessary to perform high quality research on chronic diseases, nutrition, and metabolism (the process by which a substance is handled in the body) at the University of Missouri. As technology changes and uses new testing methods, it is necessary to compare results from old tests, equipment and devices and new tests, equipment, or devices and the reproducibility of these measurements to make sure the results are accurate. Reproducibility means performing the same test more than once to see if the same results can be achieved each time. This study will look at the validation and reproducibility of tests and laboratory assays in participants who are healthy or affected by relevant endocrine, cardiometabolic, and musculoskeletal disorders.",[88,89,90,91,92,27,25,93,94,95,96,97,28,98],"Obesity and Obesity-related Medical Conditions","Diabetes","Atherosclerotic Disease","Heart Failure","MASH","Hyperparathyroidism","Hypoparathyroidism","Ischemic Heart Disease","Cystic Fibrosis (CF)","Chronic Kidney Disease(CKD)","Cachexia","2026-05-05",{"date":101,"type":38},"2026-05-07",{"date":103,"type":21},"2027-01-01",{"date":105,"type":21},"2030-07-01",{"name":107,"class":45},"Bettina Mittendorfer",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":82,"sex":17,"minAge":115,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":119,"briefSummary":121,"conditions":122,"keywords":126,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":4},"100634321","food-trial-evaluating-fecal-abundance-of-sbd111-with-once-daily-versus-twice-daily-administration-in-healthy-adults-100634321","NCT07538167","Food Trial Evaluating Fecal Abundance of SBD111 With Once-Daily Versus Twice-Daily Administration in Healthy Adults","An Open-Label, Randomized, Parallel-Arm Food Trial Evaluating Fecal Abundance of SBD111 With Once-Daily Versus Twice-Daily Administration in Healthy Adults","Inclusion Criteria:• Provide written informed consent.\n\n* Stated availability throughout entire study period and willingness to fulfill all details of the protocol.\n* Age 35 years or older.\n* Be in general good health as determined by a screening evaluation within 30 days of the first administration of SBD111 medical foods.\n* Willing to comply with protocol and report on compliance and side effects during study period.\n* Body Mass Index between 18.5 and 40kg\u002Fm2.\n\nExclusion Criteria:\n\n* • Are currently taking probiotic or prebiotic supplements or have taken them in the past 30 days. If participant is willing to stop taking probiotic or prebiotic supplement for 30-days, they can be re-screened for eligibility and enrollment after consent.\n\n  * Unwilling to avoid probiotics\u002Fprebiotics supplements for the duration of the study.\n  * Known or suspected allergies to probiotics, maltodextrin, or berries.\n  * Received oral or parenteral antibiotics within 30 days of enrollment or prescribed antibiotics on the day of enrollment.\n  * Major surgery on the intestines or endoscopy within last 3 months.\n  * History of drug and\u002For alcohol abuse at the time of enrollment.\n  * Presence of any of the following based on participant reported health history:\n  * Clinically significant systems abnormalities based on screening questionnaire.\n  * Indwelling catheter or feeding tube.\n  * Febrile illness (oral temperature \\>37 degrees Celsius) or one or more episodes of diarrhea within 72 hours of baseline (first administration of study article).\n  * Active bowel leak, acute abdomen, colitis, or active GI disease or history of gastric or intestinal dysmotility, slowed transit time, variable small intestinal permeability, pancreatitis, or inflammatory bowel disease.\n  * History of Hepatitis B or Hepatitis C infections, cirrhosis, or chronic liver disease.\n  * Underlying structural heart disease or previous history of endocarditis or valve replacement.\n  * Immunosuppression including HIV positive, solid organ or stem cell transplant recipient, receiving any oral or parenteral immunosuppressive therapy.\n  * History of Celiac disease.\n  * History of cancer.\n\n    a. Excluding non-melanoma skin cancers or cancer more than 10 years ago.\n  * History of autoimmune disease and taking any immunosuppressant drugs.\n  * Active tuberculosis.\n  * Pregnant, planning on becoming pregnant within the next 2 months, breastfeeding, positive urine pregnancy test within 24 hours of first administration of DMA.\n  * Participants may be excluded if, in the investigator's opinion, there is evidence of cognitive impairment or dementia which is sufficient to interfere with informed consent or adherence to the study protocol. Four questions will be asked during the informed consent process to confirm participant's understanding and ability to comply. (See section 8.3)\n  * Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer participating in the study or would make it unlikely the volunteer could complete the study.\n  * Bowel movement frequency less than one per 36-hour period.\n  * If the subject has been in a recent experimental trial, these must have been completed not less than 30 days prior to this study.","35 Years",{"count":117,"type":21},80,"INTERVENTIONAL",[120],"NA","The purpose of this study is to determine whether a modified formulation and daily intake schedule of SBD111 results in similar levels of probiotic microbes in the gut compared with the currently used formulation. SBD111 is a food made of probiotic microbes (bacteria and yeast) and prebiotic dietary fibers (a form of fiber obtained from diet). SBD111 is a medical food used for the dietary management of postmenopausal bone loss.SBD111 was previously found to be safe and well tolerated in a human clinical safety study and a clinical efficacy study. Study participation will include a screening virtual visit, periodic remote questionnaires and check-in calls, and three at-home stool swab sample collections.\n\nEligible participants will be assigned to one of two SBD111 study groups evaluating different formulations and dosing schedules. Each day for a 28-day period, they will take (i) two capsules once daily or (ii) two capsules twice daily (morning and evening), depending on the study group assigned. Investigators will collect demographic information and will ask questions related to dietary intake, bowel habits, and health history. Upon enrollment into the study, participants will receive six at-home stool sample collection kits, two each for baseline, Week 1, and Week 4 analysis. Samples will be collected at home and mailed to a Sōlaria Biō for analysis of the bacterial community that lives in the intestine (the gut microbiome). During the study, participants will also be asked to complete brief questionnaires related to gastrointestinal symptoms, cognitive function, well-being, and sleep. On days 7 and 28 of the study, they will be asked to complete a brief adherence questionnaire and discuss any adverse (negative) events.\n\nAll participants will receive compensation in the form of gift cards for completing study procedures and returning stool samples. Participants will receive a $50.00 gift card after completing the Week 1 study procedures and after receipt of the mailed baseline and Day 7 stool swab samples. Participants will receive a $150.00 gift card after completing the Week 4 study procedures and after receipt of the mailed Week 4 stool swab sample.",[28,25,123,124,125],"Menopause Related Conditions","Probiotic Intervention","Synbiotics",[127,128,129,28,25,130],"Probiotic","Synbiotic","Bone Loss","Fully Remote","NOT_YET_RECRUITING","2026-04-15",{"date":134,"type":38},"2026-04-20",{"date":136,"type":21},"2026-04",{"date":138,"type":21},"2027-02",{"name":140,"class":141},"Solarea Bio, Inc","INDUSTRY",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":149,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":118,"phases":152,"briefSummary":154,"conditions":155,"keywords":156,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":162,"leadSponsor":164,"locationsCount":46},"100629364","phase-1-veverimer-to-decrease-net-acid-excretion-and-bone-resorption-in-adults-with-osteopenia-100629364","NCT07473713","Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia","Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia: a Dose-finding Randomized Controlled Trial","Inclusion Criteria:\n\n1. Community dwelling adults age 50 years and older (approximately equal numbers of men and women).\n2. Men should be sterile or agree to use contraception throughout the study.\n3. Women must be postmenopausal, defined as no menses in the last 5 years (to reduce variability in change in bone resorption since menopause prompts a rapid increase in bone resorption).\n4. Osteopenia will be defined as a bone mineral density (BMD) T-score at the lumbar spine, femoral neck, or total hip lower than -1 or higher than -2.5.\n5. On a prescreening interview, candidates must report a usual diet associated with an acid load by our validated short questionnaire.\n6. Estimated glomerular filtration rate (eGFR) must be 45 ml\u002Fmin or greater.\n7. Participants must agree not to change their exercise pattern or medication use during the study.\n8. Participants must agree not to change their pattern of supplement use and not to use antacids during the study because most calcium supplements and other antacids add alkali.\n9. Participants must agree to not change their eating habits or intentionally change their weight.\n\nExclusion Criteria:\n\n1. Normal BMD T-scores at all spine and hip sites, osteoporosis based on BMD T-score of -2.5 or less\n2. Respiratory illness in last month\n3. Chronic obstructive pulmonary disease (COPD)\n4. Asthma\n5. Nausea\u002Fvomiting in last month\n6. Dysphagia\n7. Malabsorption\n8. Inflammatory bowel disease\n9. Chronic diarrhea (defined as loose bowel movements daily) or constipation (≤ 2 stools per week)\n10. Insulin-requiring diabetes or fasting plasma glucose \\>125 mg\u002Fdl\n11. Untreated thyroid disease\n12. Cirrhosis\n13. Current unstable heart disease\n14. Malignancy (except non-melanoma skin cancer) or cancer therapy in last year\n15. Alcohol use \\>2 drinks\u002Fday.\n16. Individuals who are unable to provide informed consent due to cognitive impairment.","50 Years",{"count":151,"type":21},60,[153],"PHASE1","The goal of this clinical trial is to learn if veverimer will reduce urinary net acid excretion leading to reduced bone resorption in healthy adults with osteopenia. The main questions it aims to answer are:\n\n* How much does each dose of veverimer (vs. placebo) reduce 24-hr urinary net acid excretion.\n* Describe the safety of veverimer based on changes in serum bicarbonate and potassium.\n* Assess the changes in bone resorption.\n* Assess the changes in bone formation.\n* Explore the effect of veverimer on physical performance.\n\nParticipants will:\n\n* Take veverimer or placebo every day or every other day for 8 weeks\n* Visit the clinic a total of 8 times (including screening) for checkups and testing\n* Keep a medication diary tracking each day they take the study drug",[28],[28,157],"veverimer","2026-03-31",{"date":160,"type":38},"2026-04-06",{"date":132,"type":21},{"date":163,"type":21},"2028-05-01",{"name":165,"class":45},"Tufts Medical Center",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":82,"sex":173,"minAge":174,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":118,"phases":178,"briefSummary":180,"conditions":181,"keywords":184,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":74},"100607653","phase-2-resistance-training-and-rapamycin-to-enhance-bone-formation-in-postmenopausal-women-100607653","NCT07191353","Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women","StrongBone","Inclusion Criteria:\n\n* Women aged 60-75 years old, any ethnicity.\n* Participants with T- score between \\\u003C 1.0 and \\> -2.5 measured by DXA scan within 6 months of the first day of the study.\n* Adequate cognitive function to be able to give informed consent.\n\nExclusion Criteria:\n\n* Osteoporosis and fracture history\n\n  * Participants with osteoporosis (defined by DXA scan \\\u003C 6 months old: low bone mass, T-score \\\u003C -2.5 or hip fracture or clinical compression fracture of the spine).\n  * History of low energy fractures within last 6 months. Health conditions limiting exercise\n  * Health conditions that could limit walking and weightbearing exercise (for instance recent surgery, mobility limitation)\n  * Participants with impaired wound healing or history of a chronic open wound Bone metabolism disorders\n  * Primary hyperparathyroidism.\n  * Known vitamin D deficiency (\\\u003C25 nM) (re-test after substitution acceptable).\n  * Known disorders affecting bone metabolism, e.g., uncontrolled thyrotoxicosis, severe renal impairment (eGFR \\\u003C 30) or impaired liver function (baseline phosphatase higher than twice upper limit (105 U\u002FL)), active rheumatic diseases, celiac disease, severe chronic obstructive lung disease (COPD), hypopituitarism, or Cushing's disease.\n  * Previous use of bone antiresorptive or bone anabolic drugs within the last 5 years.\n\nMedication use and health conditions\n\n* Use of anabolic steroids in the previous year.\n* Use of antiresorptive therapy in the previous year.\n* Known medication\u002Fsupplements affecting bone in the previous year.\n* Diabetes type 1 and 2.\n* Heart failure similar to NYHA Class IV.\n* Treatment with drugs known to affect cytochrome P450 3A due to its role in everolimus metabolism, excluding strong CYP3A4 inhibitors or inducers, while allowing weak and intermediate inhibitors or inducers. Patients on the following drugs will be excluded from the trial: Ketoconazole, Itraconazole, Posaconazole, Voriconazole, Telithromycin, Clarithromycin, Nedazodone, Ritonavir, Atazanavir, Saquinavir, Darunavir, Indinavir, Nelfinavir, Rifampicin, Dexamethasone, Carbamazepine, phenobarbital, Phenytoin, Efavirenz and Nivirapine.\n* History of coagulopathy or medical condition requiring long-term anticoagulation.\n\nBlood disorders and other health concerns\n\n* Anemia - Hg \\\u003C 5,59 mmol\u002FL, Leukopenia - white blood cells (WBC) \\\u003C 3,5 x 10⁹\u002FL, Neutropenia absolute neutrophil count \\\u003C 2,0 x 10⁹\u002FL, or Platelet count - platelet count \\\u003C 125 x 10⁹\u002FL.\n* Insufficiently treated dyslipidemia with LDL-c \\> 4,9 mmol\u002FL and family history of dyslipidemia, Total cholesterol \\> 9,1 mmol\u002FL, or triglycerides \\> 9,9 mmol\u002FL.\n\nImmunosuppressive and current cancer Treatment\n\n* Scheduled for immunosuppressant therapy for transplant or scheduled to undergo chemotherapy or any other treatment for malignancy\n* Any form of clinically relevant primary or secondary immune dysfunction or deficiency Cardiovascular and heart conditions\n* Unstable ischemic heart disease.\n\nAllergies\n\n* Known allergy to rapamycin or rapalogs. Language limitations\n* The study will exclude participants with inability to speak and understand Danish and with inability to cooperate.","FEMALE","60 Years","75 Years",{"count":177,"type":21},148,[179],"PHASE2","The aim of the present clinical trial is to examine the effects of everolimus, resistance training, or their combination on bone and muscle health formation in elderly women aged 60-75 years. The main questions it aims to answer are:\n\nCan rapamycin's analog (Everolimus), resistance training, or their combination, enhance bone formation and muscle functions in elderly women compared to non-treatment controls.\n\nParticipants will be randomized 1:1:1:1 to one of the following treatment regimens:\n\n* Oral everolimus 5 mg once a week.\n* Oral placebo once a week.\n* Oral everolimus 5 mg once a week plus resistance training RT 1 hour, 3 times weekly.\n* Oral placebo once a week plus resistance training RT 1 hour, 3 times weekly.\n\nDuring the study there will be a total of 5-7 visits, where the participants will undergo the following:\n\n* Blood samles\n* DXA-, HRpQCT- (only Odense Universitetshospital) and MRI-scans\n* Muscle- and bone biopsies\n* Quality of life questionnaires\n* Testing of muscle funtion\n* Metabolic studies of muscle and bone protein turnover using labelling with deuturated water",[182,28,183],"Healthy","Osteoporosis Risk",[185,186,187,188,189],"Postmenopausal Women","Rapamycin","Bone formation","Muscle functions","Healthy aging",{"date":160,"type":38},{"date":192,"type":38},"2025-10-20",{"date":194,"type":21},"2027-03-01",{"name":196,"class":45},"Odense University Hospital",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":17,"minAge":204,"maxAge":18,"enrollmentInfo":205,"targetDuration":4,"studyType":118,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":46},"100624680","rems25-study-on-the-use-of-rems-technology-in-diseases-commonly-associated-with-reduced-bone-mineral-density-bmd-100624680","NCT07412782","REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)","Observational Study for the Assessment of Bone Mineral Density (BMD) Using REMS Technology","Inclusion Criteria:\n\n* Written informed consent from adult patients or parents\u002Flegal guardians\n* Age between 5 and 18 years\n* Both sexes and all ethnicities\n* Known condition negatively affecting bone health\n\nExclusion Criteria:\n\n\\- Age below 5 years or over 18 years","5 Years",{"count":85,"type":21},[120],"This study evaluates bone mineral density (BMD) in pediatric patients aged 5-18 years with conditions negatively affecting bone health, using REMS (Radiofrequency Echographic Multi Spectrometry), a non-invasive and radiation-free ultrasound technology. Bone health is crucial during childhood, when peak bone mass develops, and reduced BMD is associated with increased fracture risk. DXA is the current reference method but has limitations in children, including radiation exposure and growth-related measurement issues. REMS has been validated in adults and shows promise in pediatrics, despite the lack of reference values. The study is a single-center, national, non-profit interventional study lasting about 12 months. Participants will undergo REMS BMD measurement, clinical history collection, and assessment of anthropometric and pubertal parameters, with prior DXA data collected when available. The primary aim is to describe BMD values measured by REMS in pediatric osteoporosis, with secondary aims including subgroup analyses and comparison with DXA. A sample of 100 patients is planned. Statistical analyses will assess BMD distributions, correlations with clinical variables, and agreement between REMS and DXA using correlation coefficients and Bland-Altman analysis.",[209,25,210,211,212,213,214,215,28],"Osteogenesis Imperfecta","Hypogonadisms","Neoplasia","Obesity & Overweight","Malnutrition (Calorie)","Hypercortisolism","Growth Hormone Deficiency (GHD)","2026-02-13",{"date":218,"type":38},"2026-02-17",{"date":220,"type":38},"2025-12-04",{"date":222,"type":21},"2026-12-31",{"name":224,"class":45},"Meyer Children's Hospital IRCCS",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":82,"sex":17,"minAge":233,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":118,"phases":237,"briefSummary":238,"conditions":239,"keywords":240,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":74},"100607358","clinical-study-to-estimate-bone-mineral-density-with-the-porous-ultrasound-device-100607358","NCT07187518","Clinical Study to Estimate Bone Mineral Density With the POROUS Ultrasound Device","A Cross-sectional, Single-cohort, Bi-centre Clinical Investigation to Estimate Surrogate Bone Mineral Density (BMD) in Young and Middle-aged Men and Women Using Quantitative Ultrasound Imaging (POROUS)","POROUS-BMD","Inclusion criteria:\n\n* Female or male individuals aged 21 to and including 55 years.\n* Written informed consent has been obtained.\n\nExclusion criteria:\n\n* Presence of diseases that rule out valid measurements with the DXA and POROUS R4C ultrasound devices (e.g., fractures or metal implants in the examined bones, paralysis of the lower extremities, severe bone abnormalities).\n* Open wounds or skin infections at the measurement site of the POROUS R4C ultrasound device.\n* Inability to undergo the investigations required by the Clinical Investigation Plan (CIP) or cognitive limitations that preclude understanding of the Participant Information Sheet and the Informed Consent Document.\n* Pregnancy and breastfeeding\n* Individual is in custody by order of an authority or a court of law.\n* Close affiliation with an investigational site, e.g., employment at an investigational site, close relative of an investigator, or dependent person (e.g., student of the investigational site).","21 Years","55 Years",{"count":236,"type":21},350,[120],"Osteoporosis is a widespread medical condition among older people. It causes the bones to weaken and become more likely to break. Osteoporosis and bone fracture risk are currently evaluated by looking at clinical risk factors and measuring bone mineral density (BMD). The lower the BMD is, the higher the risk of osteoporotic fractures in the future. An X-ray device called DXA is the main tool used to diagnose osteoporosis and fracture risk clinically. DXA measures two-dimensional BMD in the hip and spine. However, DXA devices are often not readily available at the point of care.\n\nThe POROUS ultrasound device offers a different approach by measuring various properties of the outer layer of the bone in the lower leg. It has several advantages over DXA: (1) higher and three-dimensional image resolution; (2) the ability to measure bone properties without radiation; (3) portability, it is a mobile medical device; 4) lower operational costs.\n\nFor this clinical study, we will recruit men and women between the ages of 21 and 55. Most of these study participants will not have evident clinical risks for osteoporosis. The goal for including this age group is to estimate the range of BMD values for younger people before BMD declines with age. In a separate clinical study, we are recruiting older participants. The study is anticipated to last one year.\n\nOur major research questions are:\n\n* Can the POROUS ultrasound device estimate BMD?\n* How does its performance compare to DXA?\n* What is the safety of the new device?\n\nThe participants will:\n\n* answer questions about their medical history.\n* be measured for height and weight.\n* be examined with the two devices, DXA and POROUS.",[182,28,25],[25,28,241,242,243,244,245,246,247,248,249,250,251,252,31],"Bone Tissue","Diagnostic Imaging","Ultrasound","Ultrasonography","Ultrasonic Diagnosis","DEXA Scan","DXA Scan","Dual X-Ray Absorptiometry","Bone Fractures","Osteoporotic Fractures","Hip Fractures","Spinal Fractures","2025-11-17",{"date":255,"type":38},"2025-11-20",{"date":257,"type":38},"2025-11-14",{"date":259,"type":21},"2026-11-13",{"name":261,"class":141},"POROUS GmbH",{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":118,"phases":271,"briefSummary":273,"conditions":274,"keywords":276,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":288},"100574703","phase-4-zoledronic-acid-for-the-prevention-of-tdf-sparing-art-induced-bone-mass-density-loss-in-treatment-naive-hiv-positive-individuals-100574703","NCT06762730","Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals","A Single Dose Intravenous Administration of Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals - a Prospective, Multicenter, Open-label, Randomized Control Trial","Inclusion Criteria:\n\n* Adults over age of 18 years old of any gender, social, religious or racial background.\n* Confirmed positive result for HIV infection.\n\nExclusion Criteria:\n\nPatients who received previous pharmacological agents for the prevention of HIV infection.\n\n* Women who are pregnant, lactating or those who plan to become pregnant within the trial timeframe.\n* Past history of severe drug-induced reaction (including atypical femur fractures or osteonecrosis of the jaw) or documented hypersensitivity to a bisphosphanate agent.\n* Patients with untreated hypocalcemia at screening.\n* Severe dental status",{"count":270,"type":21},110,[272],"PHASE4","The goal of this clinical trial is to learn if zolendric acid can prevent the anticipated deterioration of bone mass after antiviral treatment initiation for people that were recently diagnosed with HIV.\n\nThe main questions it aims to answer are:\n\n1. Is bone mass deterioration is significant even with the new medication currently used to treat HIV?\n2. Can one dose of Zolendric acid protect from deterioration of bone mass.\n\nResearchers will compare one dose of zolendric acid to follow-up only\n\nParticipant will:\n\n1. Provide blood samples for bone markers before antiviral treatment initiation and at 6M,12M,24M and 48M after treatment initiation\n2. Perform DXA scan soon after antiviral treatment initiation and after 12M ,24 M and 48 months\n3. Half of the patients with moderate reduction in bone mass will be treated with one dose of zolendric acid in the clinical trial, the other participants will be followed without intervention.\n4. Patients with substantial osteoporosis will be treated according to standard of care by their HMO, but will continue followup in the study.",[275,28],"HIV Infected Individuals",[28,277,278],"zoledronic acid","HIV naïve","2025-09-13",{"date":281,"type":38},"2025-09-18",{"date":283,"type":38},"2024-12-09",{"date":285,"type":21},"2032-12-01",{"name":287,"class":45},"Hadassah Medical Organization",3,{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":297,"enrollmentInfo":298,"targetDuration":4,"studyType":118,"phases":299,"briefSummary":300,"conditions":301,"keywords":306,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":46},"100590008","brief-title-the-role-of-nutrition-in-the-rehabilitation-of-patients-with-eating-disorders-after-a-vascular-stroke-100590008","NCT06961825","Brief Title: The Role of Nutrition in the Rehabilitation of Patients With Eating Disorders After a Vascular Stroke.","The Role of Nutrition in the Rehabilitation of Patients With Eating Disorders After a Vascular Stroke: A Randomized Controlled Trial Investigating the Effect of Protein Supplementation on Functional Recovery, Sarcopenia, Osteopenia, and Nutritional Status in Stroke Patients With Hypoalbuminemia.","Nutristroke","Inclusion Criteria:\n\n* Age range: Adults aged 18 to 85 years\n* Diagnosis: Patients diagnosed with a stroke (cerebrovascular accident) within the last 4 to 6 weeks\n* Serum albumin levels: Patients with low serum albumin levels (\\\u003C 3.5 g \u002F dL)\n* Nutritional intervention requirement: Patients who require nutritional intervention to support rehabilitation and nutrition\n* Informed consent: Patients who have completed the consent form for participation in the study and acceptance of the intervention\n\nExclusion Criteria:\n\n* Severe infections or serious cardiopulmonary conditions: Patients with severe infections or serious cardiopulmonary conditions requiring immediate medical intervention, which may affect nutrition and rehabilitation\n* Comorbidities: Patients with comorbid conditions such as renal or liver disease\n* History of stroke or neurological conditions: Patients with a history of stroke or other neurological conditions who do not meet the criteria for rehabilitation\n* Severe mental or psychological conditions: Patients with severe mental or psychological conditions who are unable to understand or consent to participation in the study","85 Years",{"count":85,"type":21},[120],"Brief Summary: The main objective of this thesis is to investigate the role of nutrition - specifically the administration of protein supplements (single dose and double dose) - in the rehabilitation of stroke patients with low albumin levels in relation to sarcopenia, osteopenia and functional recovery indices. The study will follow a randomized controlled trial design, incorporating clinical observation, analysis of biochemical markers, and assessment of physical and functional parameters. Participants will be randomly assigned to one of the three groups: (1) Group 1, receiving no protein supplementation (control group), (2) Group 2, receiving a single dose of protein supplement and (3) Group 3, receiving a double dose of protein supplement. The intervention will last for at least six weeks or until the biochemical markers of albumin normalize and the patient resumes regular oral intake. Biochemical assessment with be conducted through regular nutritional evaluations including measurement of serum albumin, prealbumin, C - reactive protein, creatinine, blood glucose and glycosylated hemoglobin (HbA1c), urea, electrolytes, urine albumin and additional inflammatory markers. Bone density will be assessed using DEXA, MBSR and hip measurements to determine the potential improvements resulting from the intervention. Muscle mass will be evaluated using whole - body DEXA analysis, while muscle strength and mobility will be assessed through grip strength tests and fine gait assessments. Functional recovery will be evaluated usings standardized tools for activities of daily living (Barthel Index), mental state (Geriatric Depression Scale) and quality of life (SF - 36), as well as mobility and walking tests such as the Timed Up and Go Test and 6 - Minute Walk Test. The collected data will be analyzed using appropriate statistical tools, including comparison models (ANOVA, Mann - Whitney U test) and correlation models (Pearson - Spearman). This research is expected to enhance theoretical knowledge regarding the relationship between nutrition, biochemical markers and rehabilitation outcomes in stroke patients with hypoalbuminemia. More specifically, it aims to explore the underlying mechanisms through which nutrition affects recovery - a field that remains unexplored. Additionally, the anticipated finding may contribute to the development of clinical guidelines and therapeutic approaches for the nutritional management of patients with low albumin levels, promoting personalized nutritional strategies that support effective post - stroke rehabilitation.",[302,303,27,28,213,304,305],"Stroke","Hypoalbuminemia","Protein-energy Malnutrition","Functional Decline",[307,308,309,310,311,312,313,314,315,316],"protein supplementation","nutritional intervention","albumin levels","stroke","stroke rehabilitation","eating disorders","malnutrition","nutritional assessment","sarcopenia","osteopenia","2025-04-29",{"date":319,"type":38},"2025-05-08",{"date":321,"type":21},"2025-05-05",{"date":323,"type":21},"2030-05-05",{"name":325,"class":45},"University of Ioannina",{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":82,"sex":173,"minAge":174,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":118,"phases":336,"briefSummary":337,"conditions":338,"keywords":339,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":46},"100584377","effects-of-high-intensity-interval-training-on-bone-health-in-hong-kong-older-women-100584377","NCT06888544","Effects of High-Intensity Interval Training on Bone Health in Hong Kong Older Women","Effects of High-Intensity Interval Training on Bone Health, Physical Fitness and Quality of Life in Elderly Women With Osteopenia: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* • 60 to 74 years at the start date of the project\n\n  * diagnosed with osteopenia by DXA scan screening with a BMD at the femoral neck or total hip or lumbar spine between -1 and -2.5 SD T-score below the average values\n  * Passing the PAR-Q plus screening or with the physician's approval for readiness to participate in high-intensity exercise\n  * Above the average level of 2-mins stepping showing competent aerobic fitness\n  * No restriction on physical mobility\n  * No cognitive impairment, as determined by the Chinese version of the Mini-Mental Status Examination (i.e., score \\\u003C 24)\n  * No previous substantial experiences in practicing HIIT. The written informed consent form will be collected from each participant\n\nExclusion Criteria:\n\n* • Severe chronic disease restricting high-intensity exercise\n\n  * Having cognition impairment regarded by specialists\n  * checked through medical records at HA Go app platform in the past 6 months, have concurrent medical conditions (e.g., thyrotoxicosis or hyperparathyroidism, Paget's disease, renal disease, diabetes, knee or hip osteoarthritis) and use medications (e.g., corticosteroids, estrogen, thyroxine, thiazide diuretics, or antiretroviral agents) known to affect bone metabolism during past 2 years\n  * any condition with osteoporosis, osteoporotic fractures\n  * current smoker\n  * alcohol 3 or more units per day.","74 Years",{"count":335,"type":21},48,[120],"Osteoporosis is an age-related disease, characterized by a decreased bone mass and an increased risk of fragility fractures. Osteoporosis leads to increasing mortality, disabilities, morbidity of chronic pain, and the cost of health and social care, as well as decreasing the quality of life from reduced independence and hindered physical, mental, and social well-being.\n\nA recent review and meta-analysis, investigating the association between physical activity and osteoporosis prevention in elderly people, indicated that the traditional exercise interventions (i.e., resistance training) were undertaken for 60+ mins, 2-3 times\u002Fweek for 7+ months. However, participation rates remain low in these exercise programs among older adults, in part due to a need for specialized equipment and correct techniques to prevent injury. In addition, low motivation and associated compliance with such conventional exercise is problematic among older adults.\n\nConsidering there is little evidence of HIIT benefits related to older women with osteopenia, the current study aims to evaluate the effectiveness of a 24-week HIIT intervention on bone mineral density, bone turnover markers and other health-related outcomes among Hong Kong Chinese older women.",[28],[28,340,341],"Older women","High-intensity interval training","2025-03-20",{"date":344,"type":38},"2025-03-21",{"date":346,"type":38},"2024-10-16",{"date":348,"type":21},"2026-10-15",{"name":350,"class":45},"Hong Kong Baptist University",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":175,"enrollmentInfo":357,"targetDuration":4,"studyType":118,"phases":359,"briefSummary":360,"conditions":361,"keywords":362,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":46},"100582795","a-pilot-study-of-vitamin-k2-menaquinone-7-soloways--in-patients-with-osteopeniaosteoporosis-carrying-a-vdr-gene-variant-100582795","NCT06867952","A Pilot Study of Vitamin K2 (Menaquinone-7, Soloways ™) in Patients With Osteopenia\u002FOsteoporosis Carrying a VDR Gene Variant","Inclusion Criteria:\n\n* Adults aged 40-75 years with a confirmed DXA-based diagnosis of osteopenia or osteoporosis (T-score ≤ -1.0).\n* Stable dietary habits and willingness to maintain current exercise regimen throughout the study.\n* Willingness to undergo genotyping for the VDR variant. For the VDR Variant Cohort: confirmed homozygous \"unfavorable\" variant (e.g., BsmI or ApaI).\n* For the Non-Variant Cohort: confirmed absence of the \"unfavorable\" allele (wild-type).\n\nExclusion Criteria:\n\n* Current or recent (last 3 months) use of high-dose bisphosphonates, anabolic agents (e.g., teriparatide), or selective estrogen receptor modulators (SERMs). Known allergy or hypersensitivity to vitamin K or vitamin D supplements.\n* Severe renal or hepatic dysfunction, uncontrolled hyperthyroidism, or other significant comorbidities that could confound bone metabolism assessments.\n* Pregnancy or breastfeeding.\n* Inability or unwillingness to provide informed consent or to comply with study procedures.",{"count":358,"type":21},40,[120],"This pilot, genotype-stratified clinical trial aims to evaluate the safety and preliminary efficacy of vitamin K2 (menaquinone-7, MK-7) supplementation in patients with low bone mineral density (osteopenia or osteoporosis) who carry a specific \"unfavorable\" variant in the vitamin D receptor (VDR) gene (e.g., BsmI or ApaI polymorphisms). The trial will compare improvements in bone health and related biomarkers between two cohorts: (1) homozygous carriers of the VDR variant and (2) non-variant carriers (wild-type). Investigators hypothesize that MK-7 supplementation will lead to greater improvements in bone mineral density (BMD) and bone turnover markers in the homozygous variant group due to their potentially reduced baseline response to vitamin D signaling.",[25,28],[28,25,363,364,365],"Supplements","Vitamin K2","Vitamin D","2025-03-14",{"date":368,"type":38},"2025-03-17",{"date":370,"type":38},"2024-05-03",{"date":372,"type":21},"2026-03-03",{"name":374,"class":45},"S.LAB (SOLOWAYS)",{"id":376,"slug":377,"hasResults":11,"nctId":378,"briefTitle":379,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":173,"minAge":149,"maxAge":174,"enrollmentInfo":381,"targetDuration":4,"studyType":118,"phases":382,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":46},"100567705","effect-of-manual-therapy-on-low-back-pain-in-osteopenic-postmenopausal-women-100567705","NCT06671665","Effect of Manual Therapy on Low Back Pain in Osteopenic Postmenopausal Women","Inclusion Criteria:\n\n1. Ambulatory, sedentary, non-smoking women having natural menopause at least 1 year before participation in the study.\n2. Their ages will range from 50 to 60 years old.\n3. Their BMI will be \\> 30 kg\u002Fm2.\n4. Pain before costal margin and above inferior gluteal fold.\n5. Osteopenia.\n\nExclusion Criteria:\n\n1. Osteoporosis.\n2. Having osteoporotic fractures.\n3. Having a lumbar surgery previously.\n4. Neurological disorder.\n5. Known diseases affecting bone quality (hyperthyroidism, hyperparathyroidism, hypercortisolism, etc).\n6. Receiving any medical or hormonal therapies that could affect the bone metabolism.\n7. Receiving previous manual treatment.",{"count":358,"type":21},[120],"The purpose of this study is to determine the effect of manual therapy on low back pain in osteopenic postmenopausal women.",[385,28],"Low Back Pain","2024-11-08",{"date":388,"type":38},"2024-11-12",{"date":390,"type":38},"2024-11-07",{"date":392,"type":21},"2025-06-07",{"name":394,"class":45},"Cairo University",{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":82,"sex":173,"minAge":149,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":118,"phases":405,"briefSummary":406,"conditions":407,"keywords":408,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":46},"100562715","physical-activity-guarantees-bone-density-100562715","NCT06606769","Physical Activity Guarantees Bone Density.","Fizyczne Aktywnosci Gwarantem Zdrowych Kosci","BONES","Inclusion Criteria:\n\nwomen\n\nExclusion Criteria:\n\ndiagnosed osteoporosis",{"count":404,"type":21},300,[120],"Bone tissue is crucial for overall health and quality of life, but it undergoes constant internal remodeling, leading to osteoporosis, a widespread bone disease. Regular physical activity can improve bone mineral density (BMD) and prevent osteoporosis. Studies have shown that premenopausal women with regular physical activity have greater BMD. Diagnosing bone resorption is essential, and dual-energy X-ray absorptiometry tests (DXA) and circulating microRNAs (miRNAs) may offer more prognostic potential than conventional markers. The gut microbiome may also regulate bone metabolism, with metabolites like trimethylamine N-oxide (TMAO) playing a role. A project aims to promote systematic physical activity to improve BMD and well-being, support societal mobilization, and conduct preventive examinations for osteoporosis risk. Implementing systematic prevention is important not only for health but also for reducing social and financial costs associated with osteoporosis and associated fractures.",[25,28],[409,410],"physical activity","bone mineral density","2024-10-08",{"date":413,"type":38},"2024-10-10",{"date":415,"type":38},"2024-09-13",{"date":417,"type":21},"2027-06-30",{"name":419,"class":45},"Poznan University of Physical Education",{"id":421,"slug":422,"hasResults":11,"nctId":423,"briefTitle":424,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":82,"sex":173,"minAge":149,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":427,"conditions":428,"keywords":431,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":46},"100493138","skeletal-effects-of-type-1-diabetes-on-low-trauma-fracture-risk-100493138","NCT05701254","Skeletal Effects of Type 1 Diabetes on Low-Trauma Fracture Risk","Inclusion Criteria:\n\nCriteria for enrollment of female diabetics\n\n1. No chronic disease diagnoses that may affect bone, as confirmed by the PI.\n2. Normal clinical history, physical, and clinical laboratory exam (except for usual complications of a 10+-year diabetic, i.e., \\~minimal neuropathy or retinopathy, known, but asymptomatic mild vascular disease, etc.)\n3. Glomelular Filtration Rate (GFR) \\>45 ml\u002Fmin (Renal Association lower limit for \"mild\" kidney failure).\n4. Willingness to sign a consent form.\n5. Willingness to undergo a transilial bone biopsy incision that yields 2 bone specimens.\n6. No abnormalities in clinical blood chemistry measurements (small, age-related decreases in GFR, will be permitted).\n7. Caucasian\n\nCriteria for each non-diabetic subject, compared to their matched diabetic:\n\n1. Dual-energy x-ray absorptiometry (DXA) measures (BMD, gm\u002Fcm) must be within +\u002F- 15% in total hip.\n2. Body mass index (BMI) must be within +\u002F-10%.\n3. Age must be within +\u002F- 5 years.\n4. Caucasian\n\nExclusion Criteria:\n\n1. Women who have had Type 1 diabetes for less than 10 years.\n2. Non-insulin dependent Type 1 diabetic.\n3. Less than 50 years old.\n4. Less than 5 years post menopausal.",{"count":117,"type":21},"Patients with Type 1 Diabetes Mellitus (T1DM) have a higher risk of low-trauma (osteoporotic) fracture that is 7-12 times higher than non-diabetics. The bone density of people with Type 1 Diabetes is higher at the time of fracture than in non-diabetics. This suggests the presence of underlying bone tissue mechanical defects. The potential benefits to participants would be knowledge gained about their bone density and the results of laboratory tests. On a wider scale, there may be general benefits to society because the knowledge gained from this study may help better understand the effects of diabetes on bone health",[429,28,129,430],"Type 1 Diabetes","Fractures, Bone",[432,433,434],"Bone","Cortical Bone","Mechanical Strength","2024-09-23",{"date":437,"type":38},"2024-09-25",{"date":439,"type":38},"2019-06-18",{"date":441,"type":21},"2025-01",{"name":443,"class":45},"Creighton University",{"id":445,"slug":446,"hasResults":11,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":82,"sex":173,"minAge":18,"maxAge":115,"enrollmentInfo":452,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":454,"conditions":455,"keywords":465,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":46},"100562876","the-impact-of-hormonal-contraceptive-use-and-lifestyle-factors-on-fracture-risk-and-bone-quality-in-young-female-adults-100562876","NCT06608862","The Impact of Hormonal Contraceptive Use and Lifestyle Factors on Fracture Risk and Bone Quality in Young Female Adults","The Impact of Hormonal Contraceptive Use, Body Composition, Muscular Strength and Iron Status on Fracture Risk and Bone Quality in Adult Females from 18-35 Years","FH","Inclusion Criteria:\n\n* 18 - 35 years\n* female\n* willing to participate under a pseudonym\n* occupational soldiers\n* free from chronic or acute musculoskeletal injury\n\nExclusion Criteria:\n\n* for the bioelectrical impedance: electronic implants like defibrillator, pregnancy",{"count":453,"type":21},150,"The study on hand is based on a cross-sectional design and aims to acquire 1) descriptive data on the physical state and health condition of female soldiers in the German armed forces. 2) a possible influence of different contraceptive methods as well as physical activity, body composition, strength, nutrition, and hemoglobin levels on bone health should be investigated.",[25,28,456,457,458,459,460,461,462,463,464],"Fracture Reduction","Body Composition","Nutrition","Hemoglobin","Muscle Strength","Bone Density","Contraception Behavior","Physical Activity","Menstrual Irregularities",[466,467,468,469,470,471,472,473],"impact of lifestyle factors on bone quality","impact of hormonal contraceptive use on bone quality","impact of body composition on bone quality","impact of nutrition and energy balance on bone quality","impact of amenorrhea on bone quality","impact of physical activity on bone quality","impact of the occupation soldier on bone quality","impact of muscle strength on bone quality","2024-09-19",{"date":435,"type":38},{"date":477,"type":38},"2023-10-01",{"date":479,"type":21},"2026-07-31",{"name":481,"class":45},"Bundeswehr University Munich",{"id":483,"slug":484,"hasResults":11,"nctId":485,"briefTitle":486,"officialTitle":486,"acronym":4,"eligibilityCriteria":487,"healthyVolunteers":82,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":118,"phases":489,"briefSummary":490,"conditions":491,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":4},"100464041","meniers-disease---bone-density-study-100464041","NCT05322538","Menier's Disease - Bone Density Study","Inclusion Criteria:\n\n* Definite Meniere's disease\n\nExclusion Criteria:\n\n* hyperthyroidism\n* hyperparathyroidism\n* acromegaly\n* hypogonadism\n* diabetes melitus\n* chronic renal failure\n* alcoholism\n* cushing syndrome\n* rheumatoid arthritis\n* systemic lupus erythematosus\n* ankylosing spondylitis\n* inflammatory bowel disease\n* obstructive lung disease\n* sarcoidosis\n* amyloidosis\n* celiac disease.\n* chronic treatment with bisphosphonates\n* chronic treatment with glucocorticoids\n* chronic treatment with androgen deprivation therapy\n* chronic treatment with gonadotropin releasing hormone agonist chronic treatment with aromatase inhibitor chronic treatment with loop diuretics chronic treatment with proton pump inhibitors chronic treatment with anti-seizure drugs chronic treatment with warfarin chronic treatment with SSRI chronic treatment with alpha or beta-blockers",{"count":151,"type":21},[120],"Meniere's disease is a progressive and debilitating inner ear disease characterised by vertigo and hearing loss. Several studies have linked Menierws disease with lower bone density and lower vitamin D levels. In the current prospective study definite Meniere's patients will be followed over a period of 2 year, during which repetitive measurements of bone density, vitamin D plasma levels, blood pressure as well as hearing and vestibular tests will be made. Results will be compared to healthy controls.",[492,25,28,493,494],"Meniere Disease","Vitamin D Deficiency","Vestibular Disorder","2022-08-02",{"date":497,"type":38},"2022-08-03",{"date":499,"type":21},"2022-10-01",{"date":501,"type":21},"2028-12-31",{"name":503,"class":45},"HaEmek Medical Center, Israel"]